Biophytis - Protocol Amendment of SARA-INT, a Phase 2b Clinical Trial of Sarconeos (BIO101) in Sarcopenia, Cleared by FDA and AFMPS

11 Feb 2020 08:00 CET

Company Name

BIOPHYTIS

ISN

FR0012816825

Market

Euronext Growth

Symbol

ALBPS

See attachment(s) / Voir document(s) joint(s) / Zie bijlage / Ver documento(s) em anexo

16165_912563_200211_SARAINT_Protocol_Amendment_Acceptance__EN_PR.pdf

Source

BIOPHYTIS

Provider

Les Echos

Attachments

  • Original document
  • Permalink

Disclaimer

Biophytis SA published this content on 11 February 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 February 2020 08:12:08 UTC